Furthermore, the murine model of MS, experimental autoimmune encephalomyelitis (EAE), should be used to reach two main objectives: (i) assessing the impact of Tgfb2 (either exogenously administered or endogenously produced via genetically-modified astrocytes) on inflammation, Ndrg1 expression and demyelination and (ii) evaluating the therapeutic effects of strategies aimed at inhibiting Tgfb2 (either by the administration of an anti-Tgfb2 monoclonal antibody or via a conditional and inducible KO of Tgfb2 in astrocytes). The gene discussed is TGFB2; the disease is experimental autoimmune encephalomyelitis.